Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
High Dose Icotinib + SRS for EGFR+ NSCLC with Brain Metastases
NCT02726568Phase 2Unknown
- Sponsor
- Betta Pharmaceuticals
- Start
- Mar 2016
- Primary completion
- Dec 2021
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of icotinib in non-small cell lung cancer (NSCLC), brain metastases, sponsored by Betta Pharmaceuticals. Status: unknown.
02
Drugs
icotinib
03
Conditions
non-small cell lung cancer (NSCLC)brain metastases
Beyond the preview
Go deeper on NCT02726568.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02726568.